FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2167-2169 November 27, 2003 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Andersen, H. R. PubMed Citation

To the Editor: Trials have shown that thrombolysis, as compared with placebo, reduces mortality even though it is associated with increases in the rates of reinfarction and stroke.^1,2 The Danish Multicenter Randomized Study on Fibrinolytic Therapy versus Acute Myocardial Infarction (DANAMI-2) investigators (Aug. 21 issue)³ compared primary angioplasty with thrombolysis and used a combined end point of death, reinfarction, and stroke with the knowledge that the rates of the latter two would be higher after thrombolysis than they would be after angioplasty. Use of this combined outcome biased the results against thrombolysis. Moreover, long-term follow-up data on thrombolysis show that . . . [Full Text of this Article]

This article has been cited by other articles:

• Antman, E. M., Van de Werf, F. (2004). Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction. Circulation 109: 2480-2486 [Full Text]